Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Skrit37on Sep 09, 2020 9:55pm
225 Views
Post# 31531382

RE:Coming faster than expected

RE:Coming faster than expected
Euro007 wrote:
https://www.medtechdive.com/news/grail-files-for-100m-ipo-ahead-of-2021-launch-of-multi-cancer-liquid-biops/584906/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202020-09-09%20MedTech%20Dive%20%5Bissue:29548%5D&utm_term=MedTech%20Dive


The studys 12 cancer typesand the tests sensitivity rates for detecting stage I-III diseaseincluded anorectal (79%), colorectal (74%), esophageal (76%), gastric (78%), head and neck (86%), hormone receptor negative breast (64%), liver (68%), lung (59%), ovarian (67%) and pancreatic (78%) tumors, as well as multiple myeloma (71%) and lymphomas (70%), excluding leukemias. Sensitivity is garbage.....need 90% or better like Aristotle....they have one BIG thing going for them.....MONEY..... They will have to improve the sensitivity to be taken seriously
Bullboard Posts